Drug reference
ramucirumab
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Drug class
Oncology (Monoclonal antibody(Oncology))
Mechanism of action
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.
Common side effects
- Asthenia
- Neutropenia
- Fatigue
- Hypertension
- Epistaxis
- Diarrhea
Related conditions
Frequently asked questions
What drug class is ramucirumab?
ramucirumab belongs to: Oncology.
How does ramucirumab work?
Vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds VEGF receptor 2 and blocks binding of VEGFR ligands, VEGF-A, VEGF-C, and VEGF-D. As a result, ramucirumab inhibits ligand-stimulated activation of VEGF2, thereby inhibiting ligand-induced proliferation, and migration of human endothelial cells.
What are the common side effects of ramucirumab?
Asthenia, Neutropenia, Fatigue, Hypertension, Epistaxis, Diarrhea
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.